Article
Washington, DC-Supporters of H.R. 2484 are hopeful national coverage for vision rehabilitation services will become a reality in this second session of the 107th Congress.
Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis
Bausch + Lomb publishes results from phase 4 study evaluating patient-reported outcomes with Miebo in dry eye disease